Participant flow

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders · Source last updated 2025-02-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity. Pneumococcal 13-valent Conjugate Vaccine: Given IM Trivalent Influenza Vaccine: Given IM

   id

   FG000

   title

   Arm I (Trivalent Influenza Vaccine, Prevnar)

2. description

   Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity. Pneumococcal 13-valent Conjugate Vaccine: Given IM Trivalent Influenza Vaccine: Given IM

   id

   FG001

   title

   Arm II (Trivalent Influenza Vaccine, Prevnar)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         80

      2. group Id

         FG001

         num Subjects

         85

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         64

      2. group Id

         FG001

         num Subjects

         81

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         16

      2. group Id

         FG001

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice